NYSE:CBM - Cambrex Stock Price, News, & Analysis

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) issued its earnings results on Thursday, November, 8th. The biotechnology company reported $0.49 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.59 by $0.10. The biotechnology company earned $104.62 million during the quarter, compared to analyst estimates of $122.04 million. Cambrex had a net margin of 22.67% and a return on equity of 22.20%. Cambrex's revenue was down 7.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.55 EPS. View Cambrex's Earnings History.

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Cambrex.

Cambrex updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus estimate of $2.79.

5 equities research analysts have issued 12 month price objectives for Cambrex's stock. Their forecasts range from $63.00 to $75.50. On average, they anticipate Cambrex's share price to reach $69.25 in the next year. This suggests a possible upside of 60.7% from the stock's current price. View Analyst Price Targets for Cambrex.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.

Media stories about CBM stock have trended positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cambrex earned a coverage optimism score of 2.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the company's share price in the near future.

Some companies that are related to Cambrex include Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), United Therapeutics (UTHR), Catalent (CTLT), TESARO (TSRO), FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), GW Pharmaceuticals PLC- (GWPH), Horizon Pharma (HZNP), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Emergent Biosolutions (EBS) and Evotec (EVTCY).

Cambrex's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Copper Rock Capital Partners LLC (1.17%), Summit Creek Advisors LLC (0.68%), Confluence Investment Management LLC (0.28%), Scout Investments Inc. (0.27%), IMA Wealth Inc. (0.10%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Louisiana State Employees Retirement System, Confluence Investment Management LLC, Scout Investments Inc., IMA Wealth Inc. and 6 Meridian. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.

CBM stock was purchased by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Fox Run Management L.L.C. and State of Alaska Department of Revenue. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $43.09.

Cambrex has a market capitalization of $1.48 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

The official website for Cambrex is http://www.cambrex.com.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]